Leo Gordon

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. pmc Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
    Leo I Gordon
    Northwestern University Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    J Clin Oncol 31:684-91. 2013
  2. ncbi request reprint Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
    Leo I Gordon
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Ste 850, Chicago, IL 60611, USA
    Blood 103:4429-31. 2004
  3. ncbi request reprint Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
    Leo I Gordon
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Lymphoma 5:98-101. 2004
  4. ncbi request reprint A green tea component, catechin, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo
    Leo Gordon
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    Haematologica 90:290. 2005
  5. pmc PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells
    Savita Bhalla
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Cancer Res 15:3354-65. 2009
  6. ncbi request reprint Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
    Leo I Gordon
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611 2927, USA
    Semin Oncol 29:87-92. 2002
  7. ncbi request reprint Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 850, Chicago, IL, 60611, USA
    Blood 105:1265-73. 2005
  8. ncbi request reprint Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent
    Andrew M Evens
    Departments of Medicine and Pathology, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    Clin Cancer Res 10:1481-91. 2004
  9. ncbi request reprint Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Mary Beth Riley
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Semin Oncol Nurs 20:8-13. 2004
  10. ncbi request reprint Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond
    Andrew M Evens
    Division of Hematology Oncology, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Clin Lymphoma 5:S11-5. 2004

Detail Information

Publications49

  1. pmc Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
    Leo I Gordon
    Northwestern University Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    J Clin Oncol 31:684-91. 2013
    ..Our aim was to determine if failure-free survival was superior in patients treated with the Stanford V regimen compared with ABVD...
  2. ncbi request reprint Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
    Leo I Gordon
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Ste 850, Chicago, IL 60611, USA
    Blood 103:4429-31. 2004
    ..Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma...
  3. ncbi request reprint Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
    Leo I Gordon
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Lymphoma 5:98-101. 2004
    ..These results confirm that 90Y ibritumomab tiuxetan produces high response rates and durable remissions in patients with previously treated low-grade, follicular, and transformed NHL...
  4. ncbi request reprint A green tea component, catechin, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo
    Leo Gordon
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    Haematologica 90:290. 2005
  5. pmc PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells
    Savita Bhalla
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Cancer Res 15:3354-65. 2009
    ....
  6. ncbi request reprint Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
    Leo I Gordon
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611 2927, USA
    Semin Oncol 29:87-92. 2002
    ..These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise...
  7. ncbi request reprint Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N St Clair, Suite 850, Chicago, IL, 60611, USA
    Blood 105:1265-73. 2005
    ..These studies provide a rationale for clinical investigation of this novel redox-mediating agent in patients with multiple myeloma and related disorders...
  8. ncbi request reprint Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent
    Andrew M Evens
    Departments of Medicine and Pathology, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    Clin Cancer Res 10:1481-91. 2004
    ..We examined the mechanism of imexon cytotoxicity in a diverse panel of dexamethasone and chemotherapy-sensitive and -resistant myeloma cell lines...
  9. ncbi request reprint Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Mary Beth Riley
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Semin Oncol Nurs 20:8-13. 2004
    ..To detail recent developments pertaining to the efficacy and safety of radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan for patients with B-cell non-Hodgkin's lymphoma (NHL)...
  10. ncbi request reprint Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond
    Andrew M Evens
    Division of Hematology Oncology, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Clin Lymphoma 5:S11-5. 2004
    ..Radioimmunotherapy represents a safe and effective treatment modality for patients with NHL...
  11. ncbi request reprint Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Leo I Gordon
    Division of Hematology Oncology, Feinberg School of Medicine, and the Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Semin Oncol 30:23-8. 2003
    ..This treatment regimen requires a coordinated multidisciplinary approach. Oncologists play a leading role in selecting patients for (90)Y ibritumomab tiuxetan therapy and in prescribing and overseeing the treatment...
  12. doi request reprint Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation
    Jayesh Mehta
    The Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
    Leuk Lymphoma 50:1434-41. 2009
    ..We recommend a CD34 + cell dose of 6-8 x 10(6) per kg ideal body weight to optimize outcome. The possible adverse effect of higher cell doses (>8) needs further confirmation...
  13. ncbi request reprint Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum
    Beverly P Nelson
    Department of Pathology, Northwestern University, Chicago, IL 60611 2908, USA
    Leuk Lymphoma 47:1352-9. 2006
    ..A multi-parameter approach including flow cytometric and genetic studies is crucial in separating these cases...
  14. pmc The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial
    Andrew M Evens
    Lymphoma Program, Division of Hematology Oncology, The Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 North St Clair Street, Chicago, IL 60611, USA
    Clin Cancer Res 15:6462-71. 2009
    ..Motexafin gadolinium is a novel anticancer agent that targets redox-dependent pathways and enhances sensitivity of tumor cells to ionizing radiation...
  15. ncbi request reprint Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Clin Lymphoma Myeloma 7:472-4. 2007
    ..The patient subsequently underwent matched sibling reduced-intensity allogeneic transplantation and remains disease free. Further study examining denileukin diftitox in patients with relapsed/refractory ATLL is warranted...
  16. ncbi request reprint A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma
    Andrew M Evens
    Robert H Lurie Comprehensive Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Br J Haematol 140:385-93. 2008
    ..001; OS P = 0.0002). CTAP/VMAC induction followed by consolidative auto-HSCT for newly diagnosed MCL is associated with high ORR and durable survival...
  17. pmc Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family
    Andrew M Evens
    Lymphoma Program, Division of Hematology Oncology, and Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Br J Haematol 141:676-80. 2008
    ..g. 44% DLBCL vs. 11% of FL cases with moderate-to-high expression of HIF-1alpha and HIF-2alpha, P = 0.0017). These data demonstrate that HIF and the thioredoxin family are abnormally activated in lymphoma...
  18. doi request reprint Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy
    Andrew M Evens
    Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Curr Oncol Rep 12:383-94. 2010
    ..Additionally, novel therapeutics, such as adoptive immunotherapy, should continue to be explored...
  19. ncbi request reprint Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines
    Amareshwar T K Singh
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Anticancer Res 30:1131-6. 2010
    ..We hypothesized that reactive oxygen species (ROS)-generating MGd results in low-level p53 expression, making cells more susceptible to oxidant stress...
  20. pmc Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 27:1653-9. 2009
    ....
  21. pmc All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma
    Amareshwar T K Singh
    Division of Haematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Br J Haematol 150:158-69. 2010
    ..In summary, incorporation of ATRA into ND enhanced the biological activity of this retinoid in cell culture models of MCL...
  22. pmc Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
    Andrew M Evens
    DO, MSc, Division of Hematology Oncology, 676 N St Clair S, Suite 850, Chicago, IL, 60611, USA
    J Clin Oncol 28:1038-46. 2010
    ..In addition, clinical factors at diagnosis identified patients with markedly divergent outcomes...
  23. pmc Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP
    Andrew M Evens
    DO, Division of Hematology Oncology, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
    J Clin Oncol 28:1017-24. 2010
    ..CONCLUSION The expression of HIF-1alpha protein is an important independent favorable prognostic factor for survival in patients with DLBCL treated with R-CHOP...
  24. ncbi request reprint G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
    Andrew M Evens
    Division of Hematology Oncology, Lymphoma Program, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Br J Haematol 137:545-52. 2007
    ..0% and OS 91.3% (P = 0.46 and 0.67 respectively). Our experience suggests that ABVD may be safely and effectively administered at >99% dose-intensity without G-CSF support, regardless of the ANC...
  25. ncbi request reprint Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state
    Ronald B Gartenhaus
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School, Chicago, IL 60611, USA
    Clin Cancer Res 8:566-72. 2002
    ....
  26. ncbi request reprint Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies
    Andrew M Evens
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 6:289-96. 2005
    ..Various clinical trials studying MGd as a single agent and in combination with radiation and/or chemotherapy for the treatment of hematologic malignancies are ongoing...
  27. ncbi request reprint Burkitt's and Burkitt-like lymphoma
    Andrew M Evens
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine Medical School and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Curr Treat Options Oncol 3:291-305. 2002
    ..Clinical trials remain critical to determine the most effective treatment regimens that will continue to improve cure rates in this aggressive but treatable disease...
  28. doi request reprint CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease
    Katalin Kelemen
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Am J Clin Pathol 130:166-77. 2008
    ..In multivariate Cox regression analysis, CD23 status and leukemic-phase MCL were the most important factors predicting outcome...
  29. ncbi request reprint Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies
    Bo Shi
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 303 E Chicago Avenue, Chicago, IL 60611, USA
    Blood 102:297-302. 2003
    ..Our data suggest that high levels of MCT-1 protein may be associated with a high-risk subset of lymphoid neoplasms and may further support the potential role of MCT-1 in promoting human lymphoid tumor development...
  30. ncbi request reprint Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma
    Christos Emmanouilides
    Division of Hematology Oncology, University of California, Los Angeles, CA, USA
    Cancer Biother Radiopharm 22:684-91. 2007
    ..We analyzed data from clinical trials of yttrium-90-ibritumomab tiuxetan (Zevalin); Biogen Idec, Cambridge, MA) to determine its safety and efficacy in older patients with NHL...
  31. doi request reprint Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications
    Sairah Ahmed
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Leuk Lymphoma 51:1163-77. 2010
    ..A reappraisal of prior data and examination of recently published and ongoing studies will be important in recognizing the potential benefit of RIT in the treatment of NHL...
  32. pmc Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways
    Leo I Gordon
    Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    J Biol Chem 284:2080-7. 2009
    ..Manipulation of redox signaling may be beneficial in cancer patients receiving trastuzumab...
  33. ncbi request reprint Transformation of follicular lymphoma to acute lymphoblastic leukemia
    Xiaoping Sun
    Department of Pathology, Northwestern University Medical School, Chicago, Ill 60611, USA
    Arch Pathol Lab Med 126:997-8. 2002
  34. ncbi request reprint Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology and the Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 21:1263-70. 2003
    ..This study presents the safety data from 349 patients in five studies of outpatient treatment with (90)Y ibritumomab tiuxetan...
  35. ncbi request reprint Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
    Thomas E Witzig
    Mayo Clinic, 620 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:3262-9. 2002
    ..Ibritumomab tiuxetan radioimmunotherapy targets the same antigen as rituximab and has demonstrated efficacy in rituximab-naïve NHL. This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refractory follicular NHL...
  36. ncbi request reprint Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
    Gregory A Wiseman
    Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:4336-42. 2002
    ..The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population...
  37. ncbi request reprint Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:2453-63. 2002
    ....
  38. ncbi request reprint A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Chadi Nabhan
    Oncology Specialists, S C Lutheran General Hospital Cancer Care Center, Park Ridge, Illinois 60068, USA
    Leuk Lymphoma 45:2269-73. 2004
    ..These studies are currently underway...
  39. ncbi request reprint Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature
    Stephen M Ansell
    Division of Hematology Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Clin Lymphoma 5:202-4. 2004
    ....
  40. ncbi request reprint Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:1804-10. 2007
    ..Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined...
  41. ncbi request reprint Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis
    Kristen N Ganjoo
    Department of Medicine Oncology, Stanford University, CA, USA
    Leuk Lymphoma 47:998-1005. 2006
    ..In this patient population, treatment with RA-CHOP did not result in any episodes of grade 3 or 4 proteinuria, heart failure or hemorrhage. The RA-CHOP combination was generally well tolerated and safe...
  42. ncbi request reprint Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 25:4285-92. 2007
    ..To investigate the incidence of treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute myelogenous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy...
  43. ncbi request reprint Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
    Christos Emmanouilides
    Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
    Leuk Lymphoma 47:629-36. 2006
    ..The quality of disease remissions obtained when (90)Y ibritumomab tiuxetan is administered after first relapse appears to be comparable with that observed with most chemotherapy regimens in first-relapse patients...
  44. ncbi request reprint Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN, USA
    Clin Lymphoma Myeloma 7:514-7. 2007
    ..Patients weighing > 80 kg with platelet counts of >or= 150 x 10(9)/L receive a lower dose per unit of body weight. We evaluated whether this influences the safety or efficacy of treatment...
  45. ncbi request reprint Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
    Myron S Czuczman
    Roswell Park Cancer Institute, Elm and Carlton St, Buffalo, NY 14263 0001, USA
    J Clin Oncol 23:4390-8. 2005
    ..This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma...
  46. ncbi request reprint Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008
  47. ncbi request reprint Hodgkin disease/lymphoma
    Richard T Hoppe
    Stanford Comprehensive Cancer Center, USA
    J Natl Compr Canc Netw 6:594-622. 2008
  48. ncbi request reprint Hodgkin disease/lymphoma. Clinical practice guidelines in oncology
    Richard T Hoppe
    J Natl Compr Canc Netw 4:210-30. 2006
  49. doi request reprint Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder
    Lode J Swinnen
    Department of Oncology, Johns Hopkins School of Medicine, Cancer Research Building 2M89, Baltimore, MD 21231, USA
    Transplantation 86:215-22. 2008
    ..The design predated rituximab...